Simple Horton's syndrome: Modalities of treatment;La maladie de Horton simple: Modalités thérapeutiques

Presse Medicale

Volumn 33, Issue 1, 2004, Pages 41-50

  Agard, Christian ^a   Barrier, Jacques Henri ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; DAPSONE; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE; PREDNISONE ACETATE; TETRACOSACTIDE; VITAMIN D;

AGRANULOCYTOSIS; BLOOD TOXICITY; CORTICOSTEROID THERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; LUNG FIBROSIS; METHEMOGLOBINEMIA; OSTEOPOROSIS; RETINOPATHY; REVIEW; TEMPORAL ARTERITIS; TREATMENT INDICATION;

EID: 0842308170     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98474-6     Document Type: Review

References (64)

1. Salvarini C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002; 347: 261-71.
2. Hunder GG. Giant cell arteritis in polymyalgia rheumatica. Am J Med 1997; 102: 514-16.
3. e édition. Paris: Flammarion Médecine-Sciences 2000: 659-694.
4. Barrier J, Pion P, Massari R, Peltier P, Rojouan J, Grolleau JY. Approche épidémiologique de la maladie de Horton dans le département de Loire-Atlantique: 110 cas en 10 ans (1970-1979). Rev Med Interne 1982; 3: 13-20.
5. Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932; 7700-02.
6. Nordborg E, Bengtsson BA. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. Br Med J 1989; 299: 549-50.
7. Shick RM, Baggenstoss AH, Polley HF. The effects of cortisone and ACTH on periarteritis nodosa and cranial arteritis: preliminary report. Proc Staff Meet Mayo Clin 1950; 25: 492-4.
8. Chavany JA, Taptas JN. A propos d'un cas d'artérite temporale. Importance de l'artérite de Horton dans la céphalée des vieillards. Presse Med 1948; 69: 835.
9. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids. Results in fifty-five cases in which lesion was proved at biopsy. JAMA 1957; 163: 821-7.
10. Etienne SD, Chosidow O, Herson S. Les corticoïdes. Pharmacologie et thérapeutique. Ann Med Interne 1989; 140: 502-19.
11. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ, Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis·SCID chimeras. J Clin Invest 1997; 99: 2842-50.
12. Barrier JH. Treatment of giant cell arteritis. Ann Med interne 1994; 145: 533-7.
13. Liozon F. Le traitement de la maladie de Horton. Quelles modalités pour la corticothérapie? Ann Med interne 1992; 143: 83-4.
14. Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997; 81: 195-219.
15. Généreau T, Cabane J. Bénéfices des corticoïdes lors du traitement de la maladie de Horton et de la pseudo-polyarthrite rhizomélique: avantages et inconvénients. Une méta-analyse. Rev Med interne 1992; 13: 387-91.
16. Barrier JH, Tournemaine N, Maulaz D et al. Evolution, traitement et pronostic de la maladie de Horton. Ann Med Interne 1983; 134: 428-35.
17. Bengtsson BA, Malmvall BE. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Acta Med Scand 1981; 209: 337-45.
18. Huston KA, Hunder GG, Lie JT, Kennedy RH, LR. E. Temporal arteritis. A 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978; 88: 162-7.
19. Evans JM, Hunder GG. The implications of recognizing large-vessel involvement in elderly patients with giant cell arteritis. Current Opinion in Rheumatology 1997; 9: 37-40.
20. Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989; 48: 667-71.
21. Hazleman B. Laboratory investigations useful in the evaluation of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Clin Exp Rheumatol 2000; 18 (Suppl 20): S29-531
22. Weyand CM, JJ G. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999; 42: 844-53.
23. Liozon E, Boutros-Toni F, Ly K, Loustaud-Ratti V, Soria P, E. V. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003; 30: 1272-6.
24. Ponge T, Agard C, Banier JH. Biopsie d'artère temporale. La Revue du Praticien (Paris) 1999; 49: 602-4.
25. Larroque P, Clément R, Bauduceau B H et al. Le traitement de la maladie de Horton. J Mal Vasc 1989; 14: 137-147.
26. Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-18.
27. Sailler L, Juchet H, Arlet P. Traitement de la maladie de Horton simple. La Revue du Pratiden (Paris) 1999; 49: 613-17.
28. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8.
29. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1990; 17: 1340-5.
30. Chevalet P, Masseau-Imbert A, Durand-Fix MH et al. Giant cell arteritis after the age of 75. Ann Med Interne 2002; 153: 373-7.
31. Barrier JH, Magadur G, Hamidou M et al. Utilisation des bolus de méthylprednisolone à la phase initiale de la maladie de horton. Analyse des complications, rechutes et décès à un an de suivi. Rev Med Interne 1993; 14 (suppl): 444.
32. Chevalet P, Barrier JH, Pottier P et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000; 27: 1484-91.
33. Sailler P, Carreiro M, Ollier S et al. Maladie de Horton non compliquée: traitement initial par trois bolus de 500 mg de méthylprednisolone suivis de 20 mg/j d'équivalent-prednisone. Evaluation chez 15 patients. Rev Med Interne 2001; 22: 1032-8.
34. Healey LA, Wilske KR. Treatment of resistant giant cell arteritis. Arthritis Rheum 1983; 26: 930.
35. Barrier JH, Chevalet P, Ponge T. Les principes du traitement d'attaque de la maladie de Horton. Place des assauts cortisoniques. Ann Med Interne 1998; 149 (7): 448-53.
36. Proven A, Gabriel SE, Onces C, O'Fallon WM, Hunder GG. Glucocorticold therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49 (5): 703-8.
37. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041-8.
38. Godeau P, Aubert L, Guillevin L et al. Aspect clinique, évolution et pronostic de la maladie de Horton. Etude rétrospective de 47 observations. Ann Med Interne 1982; 133: 393-400.
39. Graham E, Holland A, Avery A, Ross Russel RW. Prognosis in giant cell arteritis. Br Med J 1981; 282: 269-72.
40. Hunder GG, Allen GL, Joyce JW. daily and alternate day corticosteroid regimens in treatment of giant cell arteritis, comparison in a prospective study. Ann Int Med 1975; 82: 613-18.
41. Arlet J. De la corticothérapie classique à l'assaut cortisonique. Ann Med Interne 1994; 145 (suppl2): 5-10.
42. Barrier JH, Magadur-Joly G. Aspects actuels de la corticothérapie au long cours chez les personnes âgées. L'exemple de la maladie de Horton. Ann Med Interne 1994; 145 (5uppl2): 29-33.
43. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002; 47: 29-35.
44. Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220: 465-9.
45. Delecoeuillerie G, Joly P, Cohen de Lata A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 733-9.
46. Hachulla E, Boivin V, Pasturel-Michon U et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001; 19: 171-6.
47. David-Chausse J, Dehais J, Leman A. Résultats d'une enquête régionale sur le traitement de la pseudo-polyarthrite rhizomélique et de l'artérite temporale. A propos de 242 observations traitées selon diverses modalités par les antipaludéens de synthèse, les corticoïdes et les anti-inflammatoires non stéroïdiens. Rev Rhum 1983; 50: 263-71.
48. Le Guennec R, Dromer C, Sixou L, Marc V, Coustals P, Fourni B. Traitement de la maladie de Horton: intérêt des antipaludéens de synthèse. Rev Rhum 1994; 61: 485-90.
49. Liozon F, Barrier J, Vidal E et al. La dapsone dans le traitement de la maladie de Horton. Efficacité et tolérance. Rev Med Interne 1990; 11: 364-70.
50. Wilke WS, Hoffman GS. Treatment of corticosteroids-resistant giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 59-71.
51. Hernandez-Garcia C, Soriano C, Morado C et al. Methotrexate tretment in the management of giant cell arteritis. Scand J Rheumatol 1994; 23: 295-8.
52. Van der Veen MJ, Dinant HJ, Van Booma-Frankfort C, Van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55: 218-23.
53. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-14.
54. De Silva M, Hazleman BL Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-8.
55. De Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992; 232: 373-5.
56. Pénin F, Hingray C, Tagu P, Cuny G. Evolution sous traitement de la maladie de Horton. A propos d'une série de 60 observations. Med Hyg 1983; 41: 1901-9.
57. Liozon E, Roblot P, Paire D et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford) 2000; 39: 1089-94.
58. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.
59. Jouquan J, Mottier D, Cleuziou A et al. Accidents vasculaires cérébraux précoces au cours de maladies de Horton traitées. Responsabilité du traitement corticoïde? Ann Med Interne 1984; 135: 526-9.
60. Paccalin M, Amoura Z, Roblot P, Godeau P, Becq-Giraudon B, JC P. Accidents vasculaires encéphaliques précoces après instauration d'une corticothérapie au cours de la maladie de Horton. Rev Med Interne 2000; 21: 550-4.
61. Ponge T, Barrier J, Mottier D et al. Les accidents vasculaires cérébraux au cours de la maladie de Horton. A propos de huit observations. Sem Hop Paris 1984; 60: 2365-70.
62. Cid MC, Font C, Oriristrelli J et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26-32.
63. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497-504
64. Liozon E, Herrmann F, Ly K et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001;111:211-17.